Cronos Group (CRON) Stock Price, News & Analysis

Company Overview

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Key Stats

• Today's Range: C$2.27 to C$2.44
• 50-Day Range: C$2.29 to C$2.95
• 52-Week Range: C$2.27 to C$4.28
• Volume: 145,883 shs
• Average Volume: 266,186 shs
• Market Capitalization: C$636.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$3.54
• Consensus Rating: N/A

Cronos Group Stock Analysis - MarketRank™

Cronos Group scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: N/A

Amount of Analyst Coverage

Cronos Group has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cronos Group is -13.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cronos Group is -13.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Cronos Group has a PEG Ratio of 0.12. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Cronos Group has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRON.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cronos Group does not currently pay a dividend.

Dividend Growth

Cronos Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CRON.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Cronos Group has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cronos Group this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for CRON on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cronos Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.40% of the stock of Cronos Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.99% of the stock of Cronos Group is held by institutions.

CRON Stock Analysis - Frequently Asked Questions

How have CRON shares performed this year?

Cronos Group's stock was trading at C$2.89 at the beginning of 2025. Since then, CRON shares have decreased by 16.6% and is now trading at C$2.41.
View the best growth stocks for 2025 here.

How do I buy shares of Cronos Group?

Shares of CRON stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cronos Group investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), NIO (NIO) and Aurora Cannabis (ACB).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:CRON
• CIK: N/A
• Web: www.thecronosgroup.com
• Phone: 416-504-0004
• Fax: N/A
• Employees: 450
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$3.54
• High Stock Price Target: C$3.54
• Low Stock Price Target: C$3.54
• Potential Upside/Downside: +46.9%
• Consensus Rating: N/A
• Rating Score (0-4): 0.00
• Research Coverage: 0 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 0.12
• Net Income: C$-32,779,583.58
• Net Margins: -42.65%
• Pretax Margin: N/A
• Return on Equity: -4.40%
• Return on Assets: -3.73%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 24.24
• Quick Ratio: 24.01

Sales & Book Value

• Annual Sales: C$76.86 million
• Price / Sales: 8.28
• Cash Flow: C$1.44 per share
• Price / Cash Flow: 1.67
• Book Value: C$2.96 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 264,064,704
• Free Float: N/A
• Market Cap: C$636.40 million
• Optionable: Not Optionable
• Beta: 1.02